{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T11:25:48Z","timestamp":1787829948071,"version":"build-2784847793"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:00:00Z","timestamp":1760140800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:00:00Z","timestamp":1760140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40119-025-00431-7","type":"journal-article","created":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:09:16Z","timestamp":1760195356000},"page":"651-669","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Treatment Patterns and Healthcare Resource Utilization Among Patients with Obstructive Hypertrophic Cardiomyopathy in Japan: A Claims Database Study"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5303-3186","authenticated-orcid":false,"given":"Yuika","family":"Ikeda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2366-0960","authenticated-orcid":false,"given":"Bruno Casaes","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5263-5361","authenticated-orcid":false,"given":"Aman","family":"Malhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7053-8469","authenticated-orcid":false,"given":"Thomas","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukako","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,11]]},"reference":[{"key":"431_CR1","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","volume":"35","author":"PM Elliott","year":"2014","unstructured":"Authors\/Task Force Members, Elliott PM, Anastasakis A, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35:2733\u201379. https:\/\/doi.org\/10.1093\/eurheartj\/ehu284.","journal-title":"Eur Heart J"},{"key":"431_CR2","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1253\/circj.CJ-20-0910","volume":"85","author":"H Kitaoka","year":"2021","unstructured":"Kitaoka H, Tsutsui H, Kubo T, et al. JCS\/JHFS 2018 guideline on the diagnosis and treatment of cardiomyopathies. Circ J. 2021;85:1590\u2013689.","journal-title":"Circ J"},{"key":"431_CR3","doi-asserted-by":"publisher","first-page":"e159","DOI":"10.1016\/j.jacc.2020.08.045","volume":"76","author":"SR Ommen","year":"2020","unstructured":"Ommen SR, Mital S, Burke MA, et al. 2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2020;76:e159\u2013240. https:\/\/doi.org\/10.1016\/j.jacc.2020.08.045.","journal-title":"J Am Coll Cardiol"},{"key":"431_CR4","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.117.033200","volume":"138","author":"CY Ho","year":"2018","unstructured":"Ho CY, Day SM, Ashley EA, et al. Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the sarcomeric human cardiomyopathy registry (SHaRe). Circulation. 2018;138:1387\u201398.","journal-title":"Circulation"},{"key":"431_CR5","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1056\/NEJMoa021332","volume":"348","author":"MS Maron","year":"2003","unstructured":"Maron MS, Olivotto I, Betocchi S, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med. 2003;348:295\u2013303.","journal-title":"N Engl J Med"},{"key":"431_CR6","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.jjcc.2022.09.015","volume":"81","author":"N Terasaka","year":"2023","unstructured":"Terasaka N, Spanopoulos D, Miyagoshi H, Kubo T, Kitaoka H. Estimating the prevalence, clinical characteristics, and treatment patterns of hypertrophic cardiomyopathy in Japan: a nationwide medical claims database study. J Cardiol. 2023;81:316\u201322.","journal-title":"J Cardiol"},{"key":"431_CR7","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1253\/circrep.CR-21-0001","volume":"3","author":"N Enzan","year":"2021","unstructured":"Enzan N, Matsushima S, Ide T, et al. Clinical characteristics and contemporary management of patients with cardiomyopathies in Japan\u2014report from a National Registry of Clinical Personal Records. Circ Rep. 2021;3:142\u201352.","journal-title":"Circ Rep"},{"key":"431_CR8","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1253\/circj.CJ-19-0186","volume":"83","author":"T Hirota","year":"2019","unstructured":"Hirota T, Kubo T, Baba Y, et al. Clinical profile of thromboembolic events in patients with hypertrophic cardiomyopathy in a regional Japanese cohort\u2014results from Kochi RYOMA study. Circ J. 2019;83:1747\u201354.","journal-title":"Circ J"},{"key":"431_CR9","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1253\/circrep.CR-20-0056","volume":"2","author":"T Kubo","year":"2020","unstructured":"Kubo T, Baba Y, Ochi Y, et al. Sudden cardiac death-relevant events of hypertrophic cardiomyopathy in a regional Japanese cohort\u2014results from the Kochi RYOMA study. Circ Rep. 2020;2:433\u20139.","journal-title":"Circ Rep"},{"key":"431_CR10","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1080\/00498254.2018.1495856","volume":"49","author":"MP Grillo","year":"2019","unstructured":"Grillo MP, Erve JCL, Dick R, et al. In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin. Xenobiotica. 2019;49:718\u201333.","journal-title":"Xenobiotica"},{"key":"431_CR11","doi-asserted-by":"publisher","first-page":"16571","DOI":"10.1074\/jbc.M117.776815","volume":"292","author":"RF Kawas","year":"2017","unstructured":"Kawas RF, Anderson RL, Ingle SRB, Song Y, Sran AS, Rodriguez HM. A small-molecule modulator of cardiac myosin acts on multiple stages of the myosin chemomechanical cycle. J Biol Chem. 2017;292:16571\u20137.","journal-title":"J Biol Chem"},{"key":"431_CR12","doi-asserted-by":"publisher","first-page":"190","DOI":"10.31662\/jmaj.2021-0189","volume":"5","author":"A Okada","year":"2022","unstructured":"Okada A, Yasunaga H. Prevalence of noncommunicable diseases in Japan using a newly developed administrative claims database covering young, middle-aged, and elderly people. JMA J. 2022;5:190\u20138. https:\/\/doi.org\/10.31662\/jmaj.2021-0189.","journal-title":"JMA J"},{"key":"431_CR13","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s00280-023-04535-6","volume":"91","author":"M Tsuchiya","year":"2023","unstructured":"Tsuchiya M, Obara T, Kikuchi M, Mano N. The prevalence of end-of-life chemotherapy and targeted therapy in Japan, assessed using a health claims database. Cancer Chemother Pharmacol. 2023;91:501\u20136. https:\/\/doi.org\/10.1007\/s00280-023-04535-6.","journal-title":"Cancer Chemother Pharmacol"},{"key":"431_CR14","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s40119-022-00257-7","volume":"11","author":"AT Owens","year":"2022","unstructured":"Owens AT, Sutton MB, Gao W, et al. Treatment changes, healthcare resource utilization, and costs among patients with symptomatic obstructive hypertrophic cardiomyopathy: a claims database study. Cardiol Ther. 2022;11:249\u201367.","journal-title":"Cardiol Ther"},{"key":"431_CR15","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s40256-024-00674-0","volume":"24","author":"M Butzner","year":"2024","unstructured":"Butzner M, Papademetriou E, Potluri R, Liu X, Shreay S. Differences in healthcare resource use and cost by pharmacotherapy among patients with symptomatic obstructive hypertrophic cardiomyopathy: real-world analysis of claims data. Am J Cardiovasc Drugs. 2024;24:801\u201311.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"ehae666","key":"431_CR16","first-page":"2024","volume":"45","author":"F Sedaghat-Hamedani","year":"2024","unstructured":"Sedaghat-Hamedani F, Zema C, Schultze M, et al. Assessing the alignment of obstructive hypertrophic cardiomyopathy pharmacological treatments with ESC guidelines in Germany. Eur Heart J. 2024;45:ehae666.2024.","journal-title":"Eur Heart J"},{"key":"431_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.rec.2025.04.004","author":"R Barriales-Villa","year":"2025","unstructured":"Barriales-Villa R, Escobar-L\u00f3pez L, Vilanova Larena D, et al. Clinical management and healthcare resource utilization among patients with obstructive hypertrophic cardiomyopathy in Spain: a real-world study. Rev Esp Cardiol (Engl Ed). 2025. https:\/\/doi.org\/10.1016\/j.rec.2025.04.004.","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"3","key":"431_CR18","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1002\/ehf2.15213","volume":"12","author":"F Osman","year":"2025","unstructured":"Osman F, Zema CL, Hurst M, et al. Treatment patterns, outcomes and healthcare resource utilization of obstructive hypertrophic cardiomyopathy in England. ESC Heart Fail. 2025;12(3):2034\u201346.","journal-title":"ESC Heart Fail"},{"key":"431_CR19","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1080\/14656566.2023.2219840","volume":"24","author":"A Rosenzveig","year":"2023","unstructured":"Rosenzveig A, Garg N, Rao SJ, et al. Current and emerging pharmacotherapy for the management of hypertrophic cardiomyopathy. Expert Opin Pharmacother. 2023;24:1349\u201360.","journal-title":"Expert Opin Pharmacother"},{"key":"431_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad655.3003","volume":"44","author":"A Maggioni","year":"2023","unstructured":"Maggioni A, Ronconi G, Dondi L, et al. An Italian real-world analysis of obstructive hypertrophic cardiomyopathy through a large administrative healthcare database. Eur Heart J. 2023;44: ehad655.3003.","journal-title":"Eur Heart J"},{"key":"431_CR21","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.005152","author":"A Adler","year":"2017","unstructured":"Adler A, Fourey D, Weissler-Snir A, et al. Safety of outpatient initiation of disopyramide for obstructive hypertrophic cardiomyopathy patients. J Am Heart Assoc. 2017;6:e005152. https:\/\/doi.org\/10.1161\/JAHA.116.005152.","journal-title":"J Am Heart Assoc"},{"key":"431_CR22","unstructured":"Bisoprolol fumarate tablet. Prescribing Information. https:\/\/www.nichiiko.co.jp\/english\/pdf\/Bisoprolol_2_5and_5mg.pdf. Accessed 9 Feb 2025."},{"key":"431_CR23","unstructured":"Pharmaceutical and Medical Devices Agency review report. https:\/\/www.pmda.go.jp\/files\/000217011.pdf. Accessed 9 Feb 2025."},{"key":"431_CR24","unstructured":"Cibenzoline succinate. Prescribing Information. https:\/\/pins.japic.or.jp\/pdf\/newPINS\/00004389.pdf. Accessed 9 Feb 2025."},{"issue":"7","key":"431_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12072725","volume":"12","author":"N Maurizi","year":"2023","unstructured":"Maurizi N, Chiriatti C, Fumagalli C, et al. Real-world use and predictors of response to disopyramide in patients with obstructive hypertrophic cardiomyopathy. J Clin Med. 2023;12(7):2725.","journal-title":"J Clin Med"}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-025-00431-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40119-025-00431-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-025-00431-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T16:14:33Z","timestamp":1764951273000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40119-025-00431-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,11]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["431"],"URL":"https:\/\/doi.org\/10.1007\/s40119-025-00431-7","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"value":"2193-8261","type":"print"},{"value":"2193-6544","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,11]]},"assertion":[{"value":"30 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Typo in the figure legend for figure 6 updated.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yuika Ikeda, Aman\u00a0Malhi, Thomas Laurent, and Yukako Matsuo are employees of Bristol Myers Squibb. Bruno Casaes Teixeira is an employee of Bristol Myers Squibb. Yuika Ikeda is also a PhD student at International University of Health and Welfare, Japan.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study used de-identified claims\/electronic medical record data and, therefore, did not require ethics committee review. In addition, this study did not require informed consent to be obtained from patients. This article is based on information from an existing database and does not contain any new studies with human participants or animals performed by any of the authors. Permission was obtained from the database provider, DeSC Healthcare Inc., to disclose the data for publication. This study was conducted in accordance with the International Society for Pharmacoepidemiology Guidelines for Good Pharmacoepidemiology Practices and all applicable regulatory requirements.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}